”a phase 3 company priced like a phase 2 company”.
that’s because it is a phase 2 company.
this asset had negligible data in the old phase 2 it’s almost pointless. So the part 1 of this current trial first 70 patients that takes it to the mid Mar futility analysis is effectively the phase 2 that was never done for this asset.
Ann: Quarterly Appendix 4C and Activities Report, page-37
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.005(1.16%) |
Mkt cap ! $239.5M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 44.3¢ | 42.5¢ | $634.3K | 1.458M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 26920 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |